Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Stephen G. Smoots(University of Colorado Anschutz Medical Campus), Todd M. Pitts(University of Colorado Denver)
Cited by 26